U.S. markets close in 1 hour 27 minutes

The Cannabis ETF (THCX)

NYSEArca - Nasdaq Real Time Price. Currency in USD
Add to watchlist
20.00-1.08 (-5.12%)
As of 2:32PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close21.08
Bid20.08 x 900
Ask20.14 x 800
Day's Range20.00 - 21.66
52 Week Range5.91 - 30.99
Avg. Volume389,043
Net Assets91.59M
PE Ratio (TTM)N/A
YTD Daily Total Return58.46%
Beta (5Y Monthly)0.00
Expense Ratio (net)0.70%
Inception Date2019-07-09
  • ETF.com

    Hot ETF Stories This Year: #2 Marijuana

    Marijuana ETFs are burning up the performance charts.

  • MarketWatch

    Canadian cannabis company Cronos posts wider-than-expected Q4 loss but revenue beats estimates

    Cronos Group Inc. shares slid 3% in premarket trade Friday, after the Canadian cannabis company posted a wider-than-expected loss for the fourth quarter, but revenue that beat estimates. The Toronto-based company swung to a net loss of $111.7 million, or 31 cents a share, in the quarter, after income of $61.6 million, or 17 cents a share, in the year-earlier period. Revenue net of excise taxes came to $17.0 million, up from $7.3 million a year ago. The FactSet consensus was for a loss per share of 8 cents and revenue of $13.3 million. Revenue gains were driven by continued growth in the Canadian recreational cannabis market, sales in the Israeli medical market and growth in the U.S. segment, the company said in a statement. That was partly offset by non-recurring wholesale revenue in the Canadian market in the year-earlier quarter and price cuts on various adult-use products in Canada in the recent quarter. The company wrote down $15 million of dried cannabis inventory and cannabis extracts, mostly due to price pressure in Canada. "The company may incur further inventory write-downs due to pricing pressures in the marketplace," said the statement. Cronos said its Happy Dance brand, a line of vegan, U.S. hemp-derived CBD bath and body products co-founded by actress Kristen Bell, has secured a first U.S. retailer in Ulta Beauty and expects to launch online and in-store in the coming weeks. Shares have gained 77% in the last 12 months, while the Cannabis ETF has gained 91% and the S&P 500 has gained 23%.

  • MarketWatch

    Aurora Cannabis reiterated as underperform by Jefferies after earnings 'reinforce concerns on its underlying business'

    Jefferies analyst Owen Bennett reiterated his underperform rating on Aurora Cannabis Inc. stock on Wednesday, and said second-quarter earnings released last week "only reinforced our concerns on its underlying business." Canadian sales pressure "were more pronounced than we had assumed, with little improvement on the margin profile," Bennett wrote in a note to clients. "Second, given the near-term debt overhang and its high cash burn rate, we raise questions marks on whether Aurora's balance sheet is strong enough to support a potential US push." The analyst raised his stock price target to C$9.44 ($7.51) from C$4.59, to reflect U.S. developments. The cannabis sector has rallied in recent weeks amid high hopes for reforms of U.S.' strict cannabis laws, that continue to classify the plant as a Schedule I drug, alongside heroin. The new administration is deemed more cannabis-friendly than the last one, and already Senate Majority Leader Chuck Schumer has pledged to make cannabis legislation a key part of the current Congress. "While Aurora is not as expensive as certain other Canadian peers, for the others you can make a much better case for US optionality," said Bennett. "For example, Canopy takes ownership in an MSO and Cronos is sitting on C$1bn in cash with little debt, so can buy US assets, or at least invest aggressively. The same can't be said for Aurora." The analyst lowered his full-year gross margin forecast and raised his sales, general & administration cost forecasts. Aurora's U.S.-listed shares were up 4.3% premarket, but have fallen 43% in the last 12 months, while the Cannabis ETF has gained 87% and the S&P 500 has gained 16%.